Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials in Oklahoma City, Oklahoma
3 recruitingOklahoma City, Oklahoma
Showing 1–3 of 3 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762